Europe's largest breast cancer conference will take place in Barcelona

December 04, 2001


3rd European Breast Cancer Conference (EBCC-3)
Palau de Congressos de Catalunya, Barcelona, Spain
19-23 March 2002

Visit the Federation of European Cancer Societies (FECS) website:

All bona fide media representatives receive free registration.
To register now: complete the attached form or register on the FECS website from the 8th of December, 2001.

Please contact Maria Maneiro at FECS, or tel. +32-2-7750207


Free Registration is available for bona fide media representatives.

Please complete and return this form to the EBCC-3 Secretariat, fax +32 (2) 775 02 45. ALL media are required to enclose a photocopy of their press credentials when returning this form AND to present them at the conference.

First name:

Family name:


Job Title:

Type of publication:

-Newspaper (National/Regional)*
-Magazine (N/R)*
-News Agency (N/R)*
-Scientific Journal (N/R)*
-Radio (N/R)*
-TV (N/R)*
(please specify)............................

*Please indicate whether you are National or Regional media in your own country

Area: News/ Science/ Research & Development/ Health/ Other (please specify)...................

Address: Postal code:


Telephone Intl.:


E-mail:.......................................URL/Internet address:....................

-I will attend EBCC-3, the 3rd European Breast Cancer Conference.

-I am unable to attend EBCC-3 but would like to receive daily news by fax / e-mail (delete as necessary: please note that these will be sent out overnight).

-I am not interested. Please remove my name from the database.

ECCO-the European CanCer Organisation

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to